New Parkinson's drug candidate enters early human testing
Symptom relief
Recruiting now
This early-stage study tests a single dose of SER-252 in 40 people with Parkinson's disease who experience motor fluctuations (uncontrolled movements). The main goal is to check the drug's safety and how the body processes it. Participants receive either SER-252 or a placebo, and…
Phase: PHASE1 • Sponsor: Serina Therapeutics • Aim: Symptom relief
Last updated May 15, 2026 11:53 UTC